Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

KalVista Pharmaceuticals (KALV) Current Deferred Revenue (2018 - 2025)

KalVista Pharmaceuticals' Current Deferred Revenue history spans 7 years, with the latest figure at $11.0 million for Q2 2025.

  • On a quarterly basis, Current Deferred Revenue changed N/A to $11.0 million in Q2 2025 year-over-year; TTM through Apr 2025 was $11.0 million, a N/A change, with the full-year FY2025 number at $11.0 million, changed N/A from a year prior.
  • Current Deferred Revenue hit $11.0 million in Q2 2025 for KalVista Pharmaceuticals, up from $1.3 million in the prior quarter.
  • Over the last five years, Current Deferred Revenue for KALV hit a ceiling of $11.0 million in Q2 2025 and a floor of $11.0 million in Q2 2025.